The study offers a valuable resource and integrates multiple complementary datasets to provide insights into regulatory mechanisms, although the conceptual advances are moderate and the central ...
Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million ...
WASHINGTON, April 22 (Reuters) - Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had ...
Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on developing next-generation RNA-based medicines, today announce ...
Sox9, a master regulator of cartilage formation, switches its target genes dynamically during embryonic limb development ...
Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, ...
On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended ...
Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of ...
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
A research team has uncovered a hidden layer of early growth control in mung bean by identifying a large set of previously ...
Like tiny superheroes, small, naturally occurring segments of RNA can block multiple molecular paths that cancer cells use to grow and spread, a substantial advantage over even the most advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results